PVR and hepatocellular carcinoma: The prognostic value of CD155 in clinical subgroups with low recurrent risks (AFP ≤400 ng/ml; tumour size ≤5 cm; single‐tumour lesion; Edmondson stages I–II; CNLC stage I)13 had also been investigated in HCC, and we found that the prognostic significance of CD155 remained in these subgroups (Figure 1F,G; Figure S3A–C).